A Phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab - Adusumilli, P S; Zauderer, M G; Rivière, I (Cancer Discov, 2021)